Barclays Increases Johnson & Johnson Price Target to $197, Maintains Equal Weight Rating

Barclays raised its price target on Johnson & Johnson to $197 from $176, maintaining an Equal Weight rating. The firm refreshed its estimates for the company, citing its strong balance sheet and ability to make substantial investments in research and development. Johnson & Johnson continues to benefit from its diverse portfolio, including oncology, immunology, and neuroscience, as well as its focus on high-margin, innovation-driven categories within its Innovative Medicine unit.